Copyright
©The Author(s) 2020.
World J Clin Cases. May 26, 2020; 8(10): 1878-1886
Published online May 26, 2020. doi: 10.12998/wjcc.v8.i10.1878
Published online May 26, 2020. doi: 10.12998/wjcc.v8.i10.1878
Ligliptin treatment group | Gliquidone treatment group | P value | |
Number of cases | 54 | 56 | |
UAER (μg/min) | |||
Before treatment | 110.21 (18.82) | 107.82 (20.11) | 0.522 |
After treatment | 70.32 (11.21)a | 88.42 (12.27)a | 0.000 |
BUN (mmol/L) | |||
Before treatment | 6.10 (1.12) | 6.05 (1.09) | 0.813 |
After treatment | 5.77 (1.04)a | 5.79 (1.21)a | 0.926 |
Cr (μmol/L) | |||
Before treatment | 110.38 (15.56) | 108.82 (18.81) | 0.637 |
After treatment | 108.02 (12.38) | 107.22 (11.87) | 0.730 |
CysC (mg/L) | |||
Before treatment | 1.74 (0.30) | 1.78 (0.33) | 0.508 |
After treatment | 1.65 (0.33)a | 1.67 (0.35)a | 0.759 |
- Citation: Zhang J, Du YL, Zhang H, Sui H, Hou WK. Ligliptin for treatment of type 2 diabetes mellitus with early renal injury: Efficacy and impact on endogenous hydrogen sulfide and endothelial function. World J Clin Cases 2020; 8(10): 1878-1886
- URL: https://www.wjgnet.com/2307-8960/full/v8/i10/1878.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i10.1878